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Abstract 
Integrins are cell surface receptors with bi-directional signaling capabilities that can bind to 
adhesion molecules in order to mediate homing of leukocytes to peripheral tissues. Gut-
selective leukocyte homing is facilitated by interactions between α4β7 and its ligand 
MAdCAM-1, while retention of lymphocytes in mucosal tissues is mediated by αEβ7 binding 
to its ligand E-cadherin. Therapies targeting gut-selective trafficking have shown efficacy in 
inflammatory bowel disease (IBD), confirming the importance of leukocyte trafficking in 
disease pathobiology. This review will provide an overview of integrin structure, function and 
signaling, and highlight the role that these molecules play in leukocyte homing and retention. 
Anti-integrin therapeutics, including gut-selective antibodies against the β7 integrin subunit 
(etrolizumab) and the α4β7 integrin heterodimer (vedolizumab and abrilumab), as well as the 
non-gut selective anti-α4 integrin (natalizumab), will be discussed as well as novel targeting 
approaches using small molecules.  
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Introduction 
Inflammatory bowel disease (IBD), which includes patients diagnosed with Crohn’s disease 
(CD) and ulcerative colitis (UC), is characterised by a dysregulated mucosal immune response 
to gut microbiota. Increased activation and recruitment of leukocytes to the gut mucosa is 
observed in patients with IBD. Leukocyte migration from the peripheral circulation into 
tissues is tightly regulated by a combination of soluble and cell-surface molecules, and 
blockade of gut-selective homing mechanisms is an effective approach for the treatment of 
IBD. In this review, we examine the role of integrins in gut-selective homing and evaluate 
current and emerging integrin-targeting therapies.  
Integrin structure, activation and signaling 
Integrins are broadly expressed transmembrane glycoproteins of >1500 amino acids that 
mediate cell-cell and cell-extracellular matrix interactions.1 Twenty-four known integrin 
heterodimers have been described, made up of 18 α subunits and 8 β subunits. Dimers are 
grouped according to cell type or ligand specificity: leukocyte receptors, laminin receptors, 
collagen receptors and arginine-glycine-aspartic acid (RGD) receptors (Figure 1). RGD 
receptors are responsible for integrin-binding to extracellular matrix (ECM) proteins such as 
fibronectin or fibrinogen. The RGD sequence may be exposed in ECM upon proteolytic 
cleavage or denaturation.2 
Integrin heterodimers on the cell surface are normally found in a bent ‘closed’ resting state 
(Figure 2A) during which time they are functionally inactive.3 The cytoplasmic domain of all β 
integrins are bound to cytoskeleton proteins including α-actin, talin, vinculin, paxillin, filamin 
and tensin in the closed state. Integrins assume an ‘open’ configuration following activation 
of cell-surface receptors such as T cell receptors or chemokine receptors; this process is 
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termed ‘inside-out signaling’, as rapid intracellular signaling leads to changes in integrin 
conformation. As one of the best studied leukocyte-expressed integrins, Figure 2B 
summarises the chemokine-induced signaling cascade associated with inside-out signaling in 
αLβ2 (lymphocyte function-associated antigen 1; LFA-1) activation.4 Inside-out signaling leads 
to extension of the integrin structure and separation of the cytoplasmic tails. This 
straightening process has been termed the ‘flick knife’ or ‘switch-blade’ model,5 and improves 
integrin ‘affinity’ (ability to bind ligand).  
‘Outside-in signaling’ occurs when an integrin heterodimer binds its ligand, leading to 
activation and conformational change. Outside-in signaling occurs via integrin associated 
signaling proteins including FAK, Src and PI3K.6 Clustering of integrins on the leukocyte plasma 
membrane at the site of contact with endothelial cell adhesion molecules (CAMs) improves 
‘valency’, the number of receptor-ligand bonds, and ‘avidity’, or strength of cellular 
adhesiveness, resulting in stronger association. Mobility of integrins in the plasma membrane 
is also regulated by chemokines and contributes to cell-cell interactions.7 
Role of β7 integrins in lymphocyte migration to the gut and retention in the 
epithelium 
β7 integrin-containing heterodimers play a central role in leukocyte homing to the gut and 
retention at epithelial surfaces. The β7 integrin subunit can form a dimer with either the α4 
(CD49d) or αE (CD103, αIEL, αM290, OX-62) integrin subunit to form α4β7 (lymphocyte 
Peyer’s patch adhesion molecule-1; LPAM-1) or αEβ7 integrin respectively. The α4β7 integrin 
mediates lymphocyte migration from the circulation across the vascular endothelial barrier 
into gut-associated secondary lymphoid tissue or the intestinal lamina propria (LP) through 
interaction with its counter-receptor mucosal addressin cellular adhesion molecule-1 
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(MAdCAM-1), which is selectively expressed on the vascular endothelium within the 
intestine.8-10 Once within the intestinal mucosa, a subset of T cells then upregulate αEβ7 
which forms retentive interactions with E-cadherin expressed on intestinal epithelial cells 
(Figure 3).11  
α4β7 integrin 
Circulating T lymphocytes enter the gut either as naïve cells moving to gut-associated 
lymphoid tissue (GALT), or as circulating memory/effector cells that have previously left the 
GALT and that are returning to GALT or the LP via the systemic circulation. In either 
circumstance, lymphocytes must cross the endothelial barrier. This occurs in post capillary 
venules (PCVs) or high endothelial venules (HEV), a specialised PCV found in mesenteric lymph 
nodes (MLN) and Peyer’s patches (PP) in GALT.12,13 Although cells travel at relatively high 
velocity through these vessels, adhesion receptors on microvilli enable tethering to the vessel 
wall under physiologic shear stress (Figure 3).14,15 Unique structural and biophysical features 
of selectins and α4β7 integrin facilitate tethering and rolling.16 Selectins are a family of single-
chain transmembrane cell adhesion molecules containing an N-terminal extracellular lectin 
domain, an epidermal growth factor-like domain and a series of 2-9 consensus repeats with 
homology to sequences found in complement proteins.17 Naïve T lymphocytes expressing 
CCR7 and low levels of α4β718 initially contact endothelium in HEVs through L-selectin 
interactions, then become activated by CCR7 inside-out signaling via CCL19 and CCL21, thus 
triggering α4β7:MAdCAM-1 and αLβ2:(intercellular adhesion molecule-1)ICAM-1 interactions 
and cellular arrest.19,20 Mice lacking functional L-selectin have severely reduced numbers of 
lymphocytes in both peripheral and mucosal lymph nodes and PP, and display reduced 
leukocyte endothelial rolling during inflammation.21 
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Naïve and memory B cells also employ α4β7:MAdCAM-1 and LFA-1:ICAM-1 interactions, but 
in addition express the immunoglobulin family lectin CD22, which interacts with St6gal1-
dependent carbohydrate ligands on venules in GALT, thus conferring preferential B cell 
localisation to GALT in support of the intestinal secretory immune response.13,22 MAdCAM-1-
deificient mice have a reduced number of IgA secreting plasma cells in the small intestine 
lamina propria, and fail to mount a normal intestinal IgA response following mucosal 
immunisation.23 
MAdCAM-1 is a type 1 transmembrane adhesion molecule containing two distal 
immunoglobulin-like domains, and a mucin-like domain that can be modified by carbohydrate 
ligands for L-selectin.24,25 Murine MAdCAM-1 includes an additional, membrane-proximal 
immunoglobulin domain homologous to IgA.26,27 The activity of MAdCAM-1 as a ligand for L-
selectin is regulated by post-translational carbohydrate sulphation.24 MAdCAM-1 expression 
is constitutive in LP venules and GALT HEV, but can be further induced by pro-inflammatory 
factors such as TNFα, IL-1β and LPS during intestinal inflammation.9,28,29  
Once naïve lymphocytes enter GALT, they encounter specialised stromal cells30 and CD103+ 
migratory dendritic cells (DCs) from the gut that express retinal dehydrogenase, which 
converts vitamin A to retinoic acid (RA).13,31 CD103+ DCs can elicit a gut-homing phenotype in 
T cells32 and activation by antigen in the presence of RA induces up-regulation of α4β7 and 
CCR9 on lymphocytes.31,33 The CCR9 ligand chemokine CCL25, together with α4β7 mediates 
lymphocyte homing to the small intestine. By this mechanism, lymphocytes encountering 
CD103+ DCs become enterotropic, upregulating α4β7 integrin to enable binding to MAdCAM-
1 and homing to the gut mucosa. 
After differentiated lymphocytes return to the circulation, homing to the intestinal LP is 
facilitated by α4β7 integrin. CCL25 secreted by small intestinal endothelium is responsible for 
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recruitment of CCR9-expressing lymphocytes.34 Other chemokine receptors also assist gut 
homing including the Th17-associated receptor CCR6 and its ligand CCL20,35-37 as well as 
GPR15 and its colon-expressed chemokine-like ligand GPR15L which are of particular 
importance in colonic T cell trafficking.38-42 Gut homing memory and effector cells express 
higher levels of α4β7 than naïve T cells, enhancing their interactions and homing via 
MAdCAM-1.43 Chemokines trigger integrin activation and arrest, and cell movement across 
the endothelial barrier is then facilitated by a chemokine gradient (Figure 3).  
Regulatory T cells (TReg), which mediate a suppressive function, can be generated in gut-
draining lymph nodes and proliferate after homing to the intestine mediated by CXC3R1 and 
α4β7/MAdCAM-1 interactions.44 In β7-/- or MAdCAM-1-/- mouse models of oral tolerance, 
gut homing and intestinal expansion of TReg is impaired leading to an inability to suppress 
delayed type hypersensitivity. Similar effects on migration to the intestine have been 
observed in β7-/- T cell transfer colitis models with no subsequent effect on disease.45 
Whilst the principal integrin responsible for migration of lymphocytes to the intestine is α4β7 
interacting with its ligand MAdCAM-1,9,13,43,46 α4β7 integrin can also bind to vascular cell 
adhesion molecule-1 (VCAM-1), the expression of which may be increased in active IBD under 
the influence of pro-inflammatory cytokines such as TNFα.47,48 This could theoretically 
provide an alternative route by which α4β7+ cells can migrate to the gut, though in vivo 
homing via α4β7:VCAM-1 interactions have not been shown to date. On the other hand, 
α4β7+ lymphocytes also express α4β1, albeit at lower levels than expressed by α4β7- β1+ 
effector and memory cells.43,49 Indeed, recent evidence suggest that α4β1 can mediate T cell 
homing to the gut, contributing to α4β7+ T cell localization but also allowing α4β7- T cell 
recruitment to the ileum and/or colon, particularly in CD.50 The role of α4β1 may be 
particularly significant in the inflamed ileum, the clinical significance of which will need to be 
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elucidated using objective measures (ileocolonoscopy or MRE) of inflammation in this part of 
the bowel. αLβ2 (lymphocyte function-associated antigen; LFA-1) interacting with ICAM-1 
also contributes to gut homing.19,51,52 Confirming the relative importance of α4β7 integrin for 
the lymphocyte populations within the gut, lymphocyte migration to gut tissue in β7-/- mice 
is severely impaired, leading to poorly developed, small PP with diminished cellularity of the 
lamina propria and intraepithelial compartments.53,54 Similarly, α4β7 inhibition in mice leads 
to a reduction in B lymphocyte infiltration in the LP, as well as a reduction in lymphoid follicle 
formation in both uninflamed intestinal tissue and in acute DSS colitis.55  
Under steady state conditions and in both CD and UC, α4β7 is expressed on approximately 
half of circulating memory/effector phenotype CD4+ lymphocytes.43,56 The integrin is 
expressed by all naïve CD4+ cells at low levels. MAdCAM-1 is up-regulated in active CD and 
UC,9,57,58 and may be expressed in other organs during IBD leading to aberrant homing of 
intestinal lymphocytes and therefore extra-intestinal manifestations of the disease, for 
example in liver portal tracts during primary sclerosing cholangitis (PSC).59,60 However further 
study is required to determine the relative importance of α4β7+ leukocytes in PSC aetiology 
and whether integrin targeted therapy in this setting may be beneficial. 
αEβ7 integrin 
The αEβ7 integrin is expressed predominantly by mucosal lymphocytes and dendritic cells, 
generally referred to as CD103+ DCs, where it plays a role in adhesion or retention of these 
cells due to interactions with E-cadherin, the only known ligand for αEβ7.11,61,62  
Less than 3% of peripheral circulating T lymphocytes express the αEβ7 integrin, yet αEβ7 is 
readily observed on lymphocytes in the gut. The majority of αEβ7+ cells in the intestine are 
CD3+ T lymphocytes,63 and neither B lymphocytes nor macrophages in the gut express the 
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αEβ7 integrin.64 αEβ7 is expressed on approximately 90% of intraepithelial lymphocytes (IELs) 
and approximately 40% of T cells in the LP.63,65 The αE knockout mouse has reduced epithelial 
and LP lymphocyte numbers, however PP and splenic populations remain intact.66 E-cadherin, 
expressed on basolateral epithelial surfaces, is a member of the cadherin family of 
glycoproteins responsible for Ca2+ dependent cell-cell adhesion and cellular signaling via a 
histidine-alanine-valine sequence in the first extracellular domain.67,68 αEβ7 binds to E-
cadherin at a separate site from regions involved in maintaining epithelial polarity and para-
cellular junctions.69-71 Inside-out signaling through TCR stimulation can improve the avidity of 
αEβ7 for E-cadherin and may be a mechanism for retention of lymphocytes at the site of 
epithelial injury during inflammation.72 Outside-in signaling from binding of the αEβ7 integrin 
to E-cadherin enhances T cell proliferation.73,74 
Expression of αEβ7 integrin is regulated by transforming growth factor beta (TGFβ). 75,76 
Genes encoding both αE and β7 integrin contain the TGFβ response element.77,78 Conversely 
transcription of the α4 integrin subunit was shown to be reduced in the presence of TGFβ.78 
Indeed up to 40% of αEβ7+ T cells in the gut do not express α4β7,63 and an additive effect on 
migration to the intestinal mucosa has been shown for blocking both α4β7 and αEβ7 in 
comparison to α4β7 alone.79 Activated T cells cultured in the presence of TGFβ1 develop an 
IEL-like phenotype with increased surface expression of αEβ7.62,75,80 This suggests that αE is 
upregulated on populations of T cells after homing to the intestine and that are exposed to 
active TGFβ.  
There are key differences between αEβ7+ T cells in humans and mice. The majority of IELs 
(and hence αEβ7 expressing lymphocytes) are CD8+ in both mice and humans.81,82 Human 
αEβ7+ T cells have been demonstrated to have an inflammatory phenotype. αEβ7 expression 
is more common on effector memory (CD45RO+) than naïve (CD45RA+) T cells.83 Studies in 
 10 
peripheral blood T cells showed increased αEβ7 expression on Th9 and Th17 cells in 
comparison to TReg cells.79 In the gut, very few αEβ7 cells were observed to co-express FOXP3 
protein,63,79 and sorted αEβ7+ T cells had higher expression of inflammatory cytokines such 
as IFN, IL17, and TNFα as well as effector molecules including granzyme A.63,84 These data 
support an inflammatory role for αEβ7+ T cells in humans. 
In mice, αEβ7 integrin expression on CD4+ T cells marks a subset of potent TReg preferentially 
located in GALT and MLN, that are capable of expressing high levels of IL-10 and TGFβ1.85 
CD4+αE+ activated TReg were found to reduce the severity and increase the survival of 
recipients in a chronic graft-versus-host disease (GvHD) rodent model, and adoptive transfer 
of CD4+αE+ TReg can ameliorate disease in recipient animals.86 Murine αEβ7+ TReg subsets 
are able to suppress colitis in the adoptive T cell transfer model, express CTLA-4, have 
increased IL-10 and FOXP3, and migrate in response to CXCL9, CCL17 and CCL20 
chemokines.87,88 This suggests that in mice αEβ7+ TReg have a greater potential to migrate to 
the site of inflammation than αEβ7- cells.  
However, published data also support a pro-inflammatory role for αEβ7+ cells in mice. In the 
IL2-TNP-OVA immunisation model of colitis, inflammation is driven by a Th1 response.89 
Administration of an anti-αE mAb led to a reduction in colitis severity, accompanied by a 
reduction in LP CD4+ cells, and reduced release of IFNγ from these cells.90 In experimental 
GvHD, host-specific pathogenic CD8+ effector T cells required TGFβ for αEβ7 integrin 
expression and migration to the intestinal epithelium.91 Consistent with active TGFβ being 
expressed by intestinal epithelium, the same group demonstrated that in an allogeneic stem 
cell transplantation sarcoma mouse model, αE was preferentially expressed by intestinal 
intraepithelial CD8+ T cells and not tumour cells.92 Thus mice receiving αE deficient 
alloreactive CD8+ T cells displayed reduced severity GvHD within the intestine, whilst the 
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therapeutic graft versus tumour immune response was retained. Overall, these data 
demonstrate a more mixed role for αEβ7+ T cells in mice in comparison to humans.  
Whilst αEβ7+ T cells can be detected in interstitial lung disease, dermatitis, and during renal 
transplant rejection,75,83,93,94 αEβ7 deficient mice demonstrate a dramatic reduction in 
intestinal T lymphocytes (both LPL and IEL) with overall maintenance of mucosal T lymphocyte 
cell numbers elsewhere specifically in the bronchopulmonary, and splenic regions.66 This 
suggests therapeutic mechanisms targeting αEβ7 expressing cells in gastrointestinal disease 
should be gut-selective. 
Integrins as therapeutic targets in inflammatory bowel disease 
Early studies demonstrated that blockade with either anti-β7 or anti-MAdCAM1 monoclonal 
antibodies significantly reduced the severity of colitis in SCID mice reconstituted with CD4+ T 
cells enriched for the CD45RBhigh subpopulation.95 Emerging data suggests that trafficking to 
the inflamed ileum may be α4β7-independent in a murine adoptive transfer model.50 In 
captivity, the cotton-top tamarin monkey (Saguinus oedipus) has a well characterized 
susceptibility to the development of colonic inflammation, with histological similarities to UC, 
and responsiveness to sulphasalzine.96 Binding of α4-integrin (and hence dual α4β1 and α4β7 
inhibition) or specific α4β7 dimer blockade was shown to ameliorate colitis in this model.97,98 
α4β7 blockade was associated with a reduction in β7+ T cells in the colonic mucosa with no 
overall reduction in the peripheral circulation.98 α4 integrin blockade was also associated with 
stable peripheral lymphocyte counts with improvement in histological inflammation scores.97 
Integrin-targeted therapeutics approved or currently under investigation for IBD and their 
proposed mechanisms of action are summarised in Table 1. As cell adhesion mediators with 
bi-directional signaling capabilities, integrins play a crucial role in leukocyte homing and cell 
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differentiation in homeostasis, inflammation and cancer.99 This therefore makes integrins 
intriguing targets for therapeutic intervention, but raises the concern of undesirable off-
target effects.  
Although integrins have the potential to be gut-selective, they also are involved in leukocyte 
migration into other tissues. Of particular interest is their role in homing to the central 
nervous system (CNS). Monoclonal antibody blockade of either α4 integrin or α4β7 have 
consistently been shown to inhibit the development of experimental autoimmune 
encephalitis (EAE) in murine models, but mixed findings have been reported using β7 integrin 
blockade.100,101 More recent studies have found that β7 blockade has no effect on EAE,102 and 
are consistent with findings using anti-α4β7103 and genetic data showing that β1 is required 
for T cell migration into the CNS and subsequent EAE induction.104 Consistent with the 
requirement for β1 integrin for T cell migration, VCAM-1 but not MAdCAM-1 is found in the 
CNS,105 with maximal VCAM-1 staining in acute active plaques in multiple sclerosis (MS) 
patients in comparison to controls. Choroid plexus may also allow entry of immune cells into 
the CNS,106 and MAdCAM-1, along with ICAM-1 and VCAM-1, is upregulated on choroid plexus 
epithelium in EAE.107 The co-expression of VCAM-1 and ICAM-1 by the choroid epithelium 
suggests redundancy in entry mechanisms at this site. Taken together, these data are 
consistent with the importance of α4β1 integrin, but not β7 subunit containing integrin pairs, 
in cell migration to the CNS. 
Gut selective therapeutics that target leukocyte trafficking pathways are attractive for the 
potential to limit effects to the site of inflammation, in this case the gastrointestinal tract, 
whilst preserving immune cell trafficking to other organs.  
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Natalizumab (anti-α4 integrin monoclonal antibody) 
Natalizumab is a humanised monoclonal IgG4 antibody that selectively binds the α4 integrin 
subunit, blocking both α4β7:MAdCAM-1 as well as α4β1:VCAM-1 interactions. α4β1 is an 
integrin expressed by most leukocytes, including lymphocytes, and can bind to VCAM-1, 
fibronectin and thrombospondin.108 Early studies in CD demonstrated a significant increase 
in the number of circulating TCRαβ+ T lymphocytes, and CD19+ B lymphocytes in patients 
receiving the drug, suggesting blockade of lymphocyte transmigration to the intestine.109 In 
the ENACT-1 study, 905 CD patients were randomised to receive natalizumab 300mg or 
placebo i.v. at week 0, 4 and 8. At week 10, response rates to natalizumab vs. placebo were 
56% vs. 49% respectively (p=0.05), with a remission rate of 37% vs. 30% (p=0.12).110 In ENACT-
2, 339 responders from ENACT-1 were re-randomised to natalizumab 300mg or placebo i.v. 
every month . Response rates at 36 weeks were 61% vs. 28% (p<0.001) and remission 44% vs. 
26% (p=0.003). In ENACT-1 and ENACT-2, 8% and 9% of patients respectively tested positive 
for anti-natalizumab antibodies. In ENCORE, 509 CD patients were randomised to receive 
either placebo, or natalizumab 300mg IV at week 0, 4 and 8 with sustained response and 
remission measured over 12 weeks.111 Natalizumab treated patients had 48% response and 
26% sustained remission in comparison to 32% response and 16% sustained remission in 
patients receiving placebo.  
Natalizumab is also licensed for the treatment of relapsing-remitting MS, where α4β1 
blockade reduces the migration of T, B and plasma cells across the blood-brain barrier.112,113 
The drug was withdrawn from the market temporarily in 2005 due to an association with 
three cases of progressive multifocal leukoencephalopathy (PML), 1 in CD and 2 in MS.114-116 
α4β1 integrin binds to VCAM-1 to mediate trafficking of lymphocytes into the CNS. PML is a 
potentially fatal opportunistic brain infection caused by the John Cunningham (JC) virus, 
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leading to destruction of CNS oligodendrocytes.117 Subsequently there have been over 600 
cases of PML reported in association with natalizumab therapy in MS, with an incidence of 
4.22 per 1,000 treated patients.118 The risk of PML development is higher in those who are 
positive for JC virus antibodies and is positively correlated with prior use of 
immunosuppressants and duration of natalizumab therapy. Owing to the risk of PML, 
natalizumab is only licensed in the USA for CD under a tightly controlled risk management 
program called the TOUCH Prescribing Program. 
Another anti-integrin, efalizumab,119 a humanized monoclonal IgG1 antibody that targets αL 
integrin and blocks αLβ2 interactions with ICAM, was originally approved for moderate to 
severe psoriasis.119 When tested in an open-label study of 15 CD patients 67% showed 
response and 40% remission at 8 weeks.120 However, efalizumab was voluntarily removed 
from the market in 2009 following reports of 3 PML cases among psoriasis patients, 
precluding further study.121 
Vedolizumab (anti-α4β7 integrin) 
Vedolizumab, approved for both CD and UC is a humanised monoclonal IgG1 antibody specific 
for the α4β7 heterodimer, blocking only α4β7:MAdCAM-1 interactions and not α4β1:VCAM-
1 interactions.122,123 The gut-selective activity of vedolizumab has been confirmed by several 
experiments. Vedolizumab did not prevent CNS inflammation in a non-human primate model 
of EAE.103 Flow cytometric analysis of cerebrospinal fluid (CSF) in 14 healthy subjects 
demonstrated no significant difference in T cell numbers or phenotype after single-dose 
treatment with vedolizumab, confirming that vedolizumab does not interfere with 
lymphocyte migration to the CNS.124 In 64 healthy subjects treated with single-dose 
vedolizumab, seroconversion on parenteral administration of hepatitis B vaccine was not 
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altered as opposed to a significantly attenuated seroconversion on enteral administration of 
cholera vaccine, demonstrating the gut selective mechanism of action of vedolizumab.125  
A phase 2 placebo-controlled trial of an earlier version of vedolizumab (MLN02/MLN0002/ 
LDP-02) randomised 181 patients with active UC to placebo, or 0.5mg/kg or 2mg/kg of active 
drug intravenously on day 1 and day 29.126 Clinical and endoscopic assessment was made at 
6 weeks. Clinical remission was noted in 33% and 32% in those receiving 0.5mg/kg and 2mg/kg 
of MLN02 respectively, compared to 14% who received placebo (p=0.03). Endoscopic 
remission was seen, respectively in 28% and 12% was in those receiving 0.5mg/kg and 2mg/kg 
of MLN02, and in 8% of those receiving placebo (p=0.007). Anti-drug antibodies (ADAs) to 
MLN02 were identified in 44% of enrolled subjects. To reduce immunogenicity, vedolizumab 
was produced in Chinese Hamster Ovary (CHO) cells and tested in a small additional phase 2 
study of the reformulated form of vedolizumab.123,127 Importantly CHO-produced 
vedolizumab did not alter the epitope binding for α4β7,123 and this formulation was used in 
the phase 3 GEMINI studies in both UC and CD. 
Pivotal phase 3 clinical trials 
GEMINI 1 was an integrated trial of vedolizumab to induce and maintain remission in 895 
patients with moderate to severely active UC.128 40% of patients had previously failed anti-
TNF therapy. Clinical response was defined as a reduction in Mayo Clinic Score129 of ≥3 points 
and a decrease of ≥30% from baseline. Clinical remission was defined as a total Mayo score 
of ≤2, with no sub-score >1. Patients received a 300mg loading dose of vedolizumab or 
placebo IV at weeks 0 and 2 and clinical assessment was performed at week 6. Response rates 
for vedolizumab vs. placebo were 47% vs. 26% (p<0.001) at week 6. Patients who had 
responded to vedolizumab by week 6 were then re-randomised to vedolizumab or placebo 
every 4 or 8 weeks for maintenance therapy from week 6. At 52 weeks, 45% and 42% of those 
 16 
receiving vedolizumab every 4 and 8 weeks, respectively, were in clinical remission in 
comparison to 16% of patients who were randomised-withdrawn to placebo from week 6. 
The safety profile of vedolizumab was comparable to placebo.  
GEMINI 2 evaluated the efficacy of vedolizumab compared with placebo in the induction and 
maintenance of clinical remission in 1115 patients with moderate to severely active CD as 
assessed using the CDAI (CDAI 220-450).130 The study design was similar to GEMINI 1, with 
clinical response defined as a reduction in CDAI of ≥100 points from baseline and clinical 
remission defined as a CDAI of ≤150 points, with assessment at week 6 after 2 doses of 
vedolizumab 300mg or placebo IV at weeks 0 and 2. 50% of patients in GEMINI 2 had 
previously been exposed to anti-TNF therapy. The week 6 clinical response rates for 
vedolizumab vs. placebo were not significantly different at 31% vs. 26% (p=0.23). However, 
clinical remission rates at 6 weeks favoured vedolizumab at 15% vs. 7% (p=0.02). At 52 weeks 
of maintenance therapy 36% of patients receiving vedolizumab every 4 weeks and 39% of 
patients receiving vedolizumab every 8 weeks were in clinical remission, compared to 22% of 
placebo patients (p=0.004 and p<0.001 respectively). In this study, only 4% of patients 
developed ADAs, demonstrating that the earlier immunogenicity issues with the monoclonal 
antibody were resolved. Nasopharyngitis was seen more commonly in vedolizumab treated 
patients, with headache and abdominal pain more common in those receiving placebo. 
Overall when compared to placebo vedolizumab treatment was associated with a higher rate 
of serious adverse events (24.4% vs. 15.3%), infections (44.1% vs. 40.2%), and serious 
infections (5.5% vs. 3.0%). 
GEMINI 3 was an additional induction study assessing the efficacy, safety and tolerability of 
vedolizumab compared with placebo in moderate to severely active CD, where a high 
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proportion of patients had prior exposure to TNF antagonists.131 Of 416 randomised patients, 
76% had previously failed TNF antagonist therapy. Patients received a full induction course of 
300mg vedolizumab or placebo i.v. at weeks 0, 2 and 6, with response and remission rates 
analysed at 6 and 10 weeks. At week 6, anti-TNF failure patients experienced no difference in 
remission between vedolizumab and placebo (15% vs. 12% respectively; p=0.433). However, 
by week 10 after 3 doses of vedolizumab or placebo a higher proportion of the vedolizumab 
treated patients were in remission in comparison to placebo (27% vs. 12%; p=0.001). Anti-
TNF-naïve patients had higher remission rates of 31% at week 6 and 35% at week 10 in 
comparison to 12% and 16% of placebo patients, respectively. These data suggest that CD 
patients previously treated with anti-TNF therapy and whose disease may be considered 
refractory, may require a longer induction treatment period than patients who are anti-TNF 
naïve. 
Exposure-efficacy relationship 
The impact of prior anti-TNF antagonist treatment and of serum vedolizumab trough 
concentrations on treatment efficacy has recently been examined in a post hoc analysis of 
GEMINI clinical trial data.132 An exposure-efficacy relationship was most apparent in UC 
patients within GEMINI 1 induction, where higher trough concentrations of drug were 
associated with greater efficacy at week 6. Patients in the lowest quartile of serum trough 
drug levels had remission rates similar to placebo, while patients in the highest quartile had 
a 30% improvement over placebo remissions rates. A less steep exposure-efficacy 
relationship was observed for induction in CD patients, again with similar remission rates to 
placebo in the lowest quartile and a 14% improvement over placebo in patients that fell into 
the highest quartile of serum drug levels. These findings were not reproduced in CD studies, 
with a less clear relationship observed In GEMINI 3. Overall those with no prior anti-TNF 
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antagonist exposure, and those with higher serum albumin concentrations consistently had a 
higher probability of clinical remission. 
Based on the GEMINI clinical trial data, an exposure-response relationship appears to be more 
definitive for UC than for CD. The data for CD in the GEMINI trials is based on the use of CDAI 
as an assessment of disease activity, however, with no objective ileo-colonoscopy data to 
confirm active mucosal inflammation in the bowel. A further assessment of the exposure-
response relationship in CD will be needed when endoscopy and serum trough concentration 
data become available. 
Long term safety and efficacy data from clinical trials 
Following the pivotal GEMINI studies, further data on the long-term efficacy and safety of 
vedolizumab have emerged from an open label extension study to the Phase 2, and Phase 3 
GEMINI trials.  
Combined long term safety data integrated from the six Phase 2 and 3 trials of vedolizumab, 
representing 2830 vedolizumab-treated patients for up to 5 years duration, and a total of 
4811 person years of drug exposure to vedolizumab, showed no increased risk of infections, 
including serious opportunistic infections (e.g. disseminated TB, systemic candidiasis, 
disseminated herpes zoster, extra-intestinal CMV or pneumocystis pneumonia) nor 
malignancy, nor any cases of PML.133 The exposure-adjusted incidence of lower respiratory 
tract infections was comparable between placebo and vedolizumab groups at 7.7 (3.9-11.5) 
and 6.1 (5.3-6.8)/100 person years (PY) respectively. The GEMINI long term safety (LTS) study 
is an ongoing single arm, open label continuation of the Phase 2 and Phase 3 GEMINI UC and 
CD trials, designed to test long term effectiveness and safety of treatment with vedolizumab 
300mg i.v. dosed every 4 weeks. In addition to the patients from the GEMINI trials rolling over 
to the LTS study, a cohort of IBD patients naïve to vedolizumab who received drug open-label 
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are included. An interim analysis of the study data for both UC and CD patients enrolled from 
May 2009 up to a data cut-point of June 2013 (152 weeks – 3 years) was recently 
published.134,135  
In UC, health related quality of life (HRQL) and clinical improvements, as measured by the 
partial Mayo clinic score (pMCS; total MCS without the endoscopic subscore136) were 
observed in patients treated with vedolizumab.134 In GEMINI 1, of the 247 UC patients who 
responded to vedolizumab by week 6 and received vedolizumab in the maintenance phase, 
154 (82%) completed maintenance and were enrolled in the LTS study. Of the 154 patients 
who rolled over into the LTS study, 42 had failed anti-TNF therapy, a further 107 were TNF-
naïve and 5 patients had either been exposed to anti-TNF previously or their TNF-responder 
status was unknown. Of those patients who had data available at the time of the interim 
analysis (as observed analysis), 88% (n=120/136) remained in remission at 104 weeks and 
96% (n=70/73) were in remission at 152 weeks. The clinical remission calculations to 152 
weeks did not take into account patients who may have discontinued the LTS study due to 
lack of efficacy. Adopting a conservative approach where missing data at each study visit was 
assumed to indicate treatment failure (non-responder imputation analysis), clinical remission 
was calculated as 74%, 78% and 46% of patients after 52 weeks, 104 weeks and 152 weeks, 
respectively. However, a limitation of this approach is that patients who remained in the 
study but had not yet reached the 152-week time-point at the time of the interim analysis, 
were deemed treatment failures thus providing a more stringent assessment of drug efficacy. 
Similar long term clinical remission rates were observed whether patients had failed, or were 
naïve to anti-TNF agents. 
32 patients on every 8-week dosing of vedolizumab withdrew from GEMINI 1 before week 52 
due to lack of efficacy or worsening of symptoms, and enrolled in the LTS study where they 
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received vedolizumab infusions every 4 weeks. After 52 weeks, clinical response and 
remission were 41% and 28% respectively, an increase from 19% and 6% respectively from 
before dose increase, suggesting patients not responding to 8-weekly dosing may receive 
clinical benefit from shortening of dosing intervals to every 4 weeks.134 
The most common adverse events in the GEMINI LTS UC cohort were worsening of UC (24%), 
nasopharyngitis (23%), headache (16%), upper respiratory tract infection (15%) and arthralgia 
14%). The incidence of malignancy was <1%. Overall, 3% of patients experienced infusion 
reactions. No cases of PML were observed. 
For CD, clinical effectiveness in the LTS study was assessed using the Harvey Bradshaw Index 
(HBI).135 Clinical response was defined as a reduction in HBI of ≥3 points from baseline and 
clinical remission was defined as an HBI of ≤4. In GEMINI 2, of the 308 patients who responded 
to vedolizumab by week 6 and received vedolizumab in the maintenance phase, 146 (47%) 
completed maintenance and were enrolled in the LTS study. Of the 146 CD patients who 
rolled over into the LTS study, 57 had failed anti-TNF therapy, a further 81 were anti-TNF-
naïve and the remaining 8 patients had either been exposed to anti-TNF previously or their 
anti-TNF responder status was unknown. Of those patients who had available data at the time 
of the interim analysis, 83% (n=97/120) remained in clinical remission at 104 weeks and 89% 
(n=62/70) were in remission at 152 weeks. Similar to the analysis for UC, patients who had 
discontinued the LTS study for various reasons, including due to lack of efficacy, were not 
included in this analysis. Again, correcting for this by assuming all missing data was due to 
lack of efficacy, clinical remission was calculated in 71%, 69% and 43% of patients after weeks 
52, 104 and 152 respectively. As in the UC analysis, this approach is limited by the fact that 
some patients remain in the LTS study but had not reached the 152-week time-point at the 
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time of the interim analysis, thus providing a more stringent assessment of efficacy at the 
later time points. Similar long term clinical remission rates were observed whether patients 
had failed, or were naïve to anti-TNF agents.135 
57 patients on every 8-week dosing of vedolizumab withdrew from GEMINI 2 before week 52 
due to lack of efficacy or worsening of symptoms and enrolled in the LTS study where they 
received vedolizumab infusions every 4 weeks. After 52 weeks, clinical response and 
remission were achieved in 47% and 32% respectively, an increase from 39% and 4% 
respectively, before the dose increase, suggesting, as observed for UC, patients who lose 
response to vedolizumab dosing every 8 weeks may experience an improved clinical outcome 
by increasing the frequency of infusions.  
The most common adverse events in the GEMINI LTS CD cohort were worsening of CD (26%), 
nasopharyngitis (21%), arthralgia (20%), headache (19%), abdominal pain (18%) and nausea 
(14%). Malignancy was observed in <1% of patients and infusion reactions in 4%. No cases of 
PML were observed. 
HRQL were also assessed for up to 152 weeks of cumulative treatment in both UC and CD 
patients and showed long-term benefits.134,135 
A further 248 week (5 year) interim analysis of the LTS study has recently been reported in 
abstract form. These data demonstrate as-observed clinical remission in 90% (57/63) of UC137 
and 89% (54/61) of CD138 patients respectively on cumulative treatment who initially 
responded to vedolizumab, the majority of whom were corticosteroid free at week 248. HRQL 
improvements continued to be observed. The long-term safety of vedolizumab was 
consistent with that previously reported with 9/61 CD and 10/63 UC patients experiencing a 
serious infection. There were no cases of PML. 
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Immunogenicity 
In the GEMINI 1 and 2 studies, 56 of 1434 patients (4%) who received continuous vedolizumab 
for 52 weeks developed ADAs.133 Concomitant administration of an immunomodulator at 
baseline reduced the ADA incidence from 4% to 3%. In patients receiving vedolizumab 
induction at weeks 0 and 2, followed by placebo maintenance therapy, 18% of those not 
receiving an immunomodulator at baseline developed ADAs compared to only 3% of subjects 
who were receiving an immunomodulator at baseline. Available evidence from the GEMINI 
LTS suggests that ADA incidence is not dependent on length of drug holiday.134,135 In the 
GEMINI 1 and 2 studies, 6 UC patients and 3 CD patients had persistent ADAs, defined as two 
consecutive ADA positive results during treatment, as quantified by ELISA. Persistently 
positive ADA titres were associated with decreases in serum trough concentration of 
vedolizumab in 3 out of the 6 UC patients and 2 out of the 3 CD patients with trough 
concentrations below the limit of detection (BLQ < 0.125 µg/ml).133,139  
The assay used to detect ADAs in the GEMINI studies was drug sensitive and so potentially 
may underestimate detection of these antibodies in the presence of vedolizumab. 
Accordingly, a drug-resistant assay has been developed in Leuven, Belgium and validated 
outside of the GEMINI programme to detect ADAs in the presence of high vedolizumab 
concentrations and compared to the drug sensitive assay.140 In an induction and maintenance 
study of 179 vedolizumab patients, the drug-sensitive assay identified one patient (0.6%) as 
having developed ADAs whereas the drug resistant assay identified 4 patients respectively as 
having developed ADAs (2.2%). In 3 of the 4 patients with ADAs, antibodies developed during 
induction dosing. ADAs were transient and disappeared on serial measurement in all patients 
and no correlation with vedolizumab trough concentrations was observed. The transient 
nature of ADAs to vedolizumab and the lack of correlation with serum trough levels in this 
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small number of patients may suggest that immunogenicity does not influence treatment 
response, however further study is needed to determine the influence of ADAs on long term 
treatment efficacy and the impact of co-administration of immunomodulators.  
In the context of anti-TNF therapy the presence of ADAs is recognised as a cause of secondary 
loss of response,141 and co-administration of an immunodulator such as methotrexate or 
azathioprine has been shown to reduce ADA formation.142 However, immunomodulators are 
associated with serious adverse effects including skin and haematological malignancies.44 As 
avoidance of systemic immunosuppression via gut selectivity is a major advantage of 
vedolizumab therapy, it remains to be determined whether systemic immunosuppression is 
required in the long-term use of vedolizumab. 
Real World Clinical Experience with vedolizumab 
Clinical effectiveness and safety data from several multicenter retrospective and prospective 
cohort studies reflecting real-world clinical experience (RWE) with vedolizumab have been 
published. A recent systematic review of 6 ‘real-world’ cohort studies followed 1049 
patients.143 In this review, the most common non-infectious side effects were arthralgia (3%), 
arthritis (1%) and headache (2%). The risk of any infection was 7.8% overall. Specifically, the 
risk of gastroenteritis was 0.2%, and Clostridium difficile 1.2%. No cases of PML were 
identified in any of these studies.  
A further systematic review and meta-analysis of real world effectiveness and safety of 
vedolizumab has been completed.144 Despite clinical observations in a predominantly 
treatment-refractory IBD population over the first 3 years post approval of vedolizumab, RWE 
confirms the long-term benefit and safety of vedolizumab as demonstrated in the clinical trial 
patient population. 
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A potential role for vedolizumab in human immunodeficiency virus (HIV) 
infection? 
Advances in the development of anti-retroviral therapy (ART) for HIV have led to substantial 
reductions in mortality and longer life expectancy for HIV+ patients.145 However, chronic ART 
is required in order to suppress viral replication and to prevent rebound of viraemia.146 ART 
is associated with significant effects on patient health, including myelosuppression, lactic 
acidosis, hepatic steatosis, neuro-psychiatric complications, rash, osteonecrosis, and diabetes 
mellitus.147-149 Therefore, cost-effective alternatives with good tolerability and safety profiles 
are desirable. Emerging research highlights intriguing evidence of the importance of the gut 
and the α4β7 integrin in the pathogenesis of HIV-1. 
In HIV-1 infection, rapid viral replication occurs in the gastrointestinal tract, causing depletion 
of CD4+ T cells in the gut and formation of viral reservoirs.150 HIV-1 viral entry is mediated 
through binding of the HIV-1 envelope protein gp120 to CD4. Both CXCR4 and CCR5 and other 
G protein coupled receptors can serve as co-receptors for this viral entry. Intriguingly, gp120 
can also bind and activate α4β7,151 and in acute SIV or HIV infection the virus preferentially 
infects cells expressing high levels of α4β7.152-155 Additionally recent human data 
demonstrates that high pre-infection numbers of CD4+α4β7+ T cells is associated with 
increased rates of HIV acquisition, independent of other T cell subsets.156 α4β7 integrin is 
preferentially incorporated into HIV-1 and SIV virions during budding,157 with the α4β7 
integrin-containing virions are highest at early time points post-infection. Administration of 
anti-α4β7 antibodies before and during intravaginal SIV infection in rhesus macaques 
conferred protection from infection.158  
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A recent study has found that anti-α4β7 therapy also has a profound impact on viral 
remission.159 SIV-infected macaques received 90 days of ART initiated five weeks after 
primary intravenous SIV infection. From weeks 9 to 18 a cohort of these animals received 8 
infusions of anti-α4β7 at 3-weekly intervals and were compared to a cohort receiving ART and 
non-specific IgG infusions, dosed at the same frequency and for the same duration. Anti-α4β7 
and IgG treatment was continued following ART withdrawal at week 18, with all treatment 
being discontinued by week 32. Viraemia rebounded within a fortnight to high levels in IgG-
treated animals following ART cessation, whereas in the anti-α4β7 treated animals, viral 
suppression or transient viraemia was observed. Virologic control without ART was 
maintained for nearly 1 year following cessation of anti-α4β7 therapy, while IgG-treated 
animals had persistently high viral titers throughout the remainder of the study. Normal CD4+ 
T cell numbers were observed in the intestine and peripheral circulation of anti-α4β7 treated 
animals.  
Currently an exploratory, open label study is now recruiting HIV-1+ patients to investigate the 
safety and efficacy of vedolizumab in controlling HIV-1 infection upon discontinuation of 
ART.160  
Etrolizumab (anti-β7 integrin) 
Etrolizumab (rhuMAbBeta7) is a humanised IgG1 monoclonal antibody specific for the β7 
integrin subunit. Through binding to β7 integrin, this drug has the dual effect of blocking gut 
homing α4β7:MAdCAM-1 interactions, and also antagonises lymphocyte retaining αEβ7:E-
cadherin interactions. It is a humanised version of the rat monoclonal antibody FIB504, which 
was unique among a panel of anti-β7 integrin antibodies in blocking all known α4β7-
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dependent interactions, including T cell aggregation, and T cell binding to fibronectin and 
VCAM-1, in addition to MAdCAM-1.161  
To date, published phase 2 etrolizumab studies have only been performed in UC patients,162 
although recent phase 3 data has been published for both UC and CD in abstract form.163,164 
A combined single ascending dose, and multiple dosing Phase 1 placebo-controlled study 
demonstrated no dose limiting toxicity, and no infusion or injection site reactions with 
etrolizumab.165 Anti-etrolizumab antibodies were detected in 2 of 38 drug-treated patients. 
In the EUCALYPTUS Phase 2 study, 124 patients with moderately to severely active UC were 
randomised 1:1:1 to subcutaneous etrolizumab 100mg at week 0, 4 and 8 (with placebo at 
week 2) or a loading dose of 420mg at week 0, followed by 300mg at week 2, 4 and 8, or 
placebo.162 The primary end-point was remission at week 10 defined as a Mayo Clinic Score 
of ≤2 with no individual subscore >1. At week 10, 0% of the placebo-controlled group were in 
remission, compared to 21% of the 100mg etrolizumab group and 10% in the 300mg plus 
loading dose group. In those patients who were anti-TNF-naïve the remission rates were 0% 
for placebo, 44% for the 100mg etrolizumab group and 25% for 300mg plus loading dose 
group. This was in comparison to poor remission rates in anti-TNF-experienced patients with 
remission rates of 0% for placebo, 5% for the 100mg etrolizumab group and 4% for the 300mg 
plus loading dose group. Post-hoc analysis presented in abstract form showed no difference 
between dose groups when the Physician’s Global Assessment component was removed from 
the calculation of efficacy by Mayo Clinic Score.166 Phase 3 studies in UC and CD are currently 
recruiting, with interim data from an open label induction cohort in UC showing a reduction 
in stool frequency and rectal bleeding in anti-TNF-refractory patients receiving etrolizumab 
as early as 4 weeks post-treatment.167  
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Further post-hoc analysis of colonic biopsies stratified patients by baseline whole-biopsy gene 
expression or IHC expression of the αE integrin subunit. High or low expression in each case 
was defined as above or below, respectively, a median cut-off for the cohort. In anti-TNF-
naïve patients with high gene or IHC expression of αE, remission was further enriched at 67% 
in the 100mg etrolizumab group and 50% in the 300mg plus loading dose group. Sequencing 
studies showed similar predictive potential for αE and granzyme A, an effector molecule 
expressed by a subset of αE+ T cells.84 
More recently, data regarding etrolizumab therapy in anti-TNF refractory UC has been 
presented in abstract form.164 The ongoing, placebo-controlled Phase 3 HICKORY study is 
evaluating etrolizumab for the induction (week 14) and maintenance of remission (week 66) 
in patients with moderate to severe UC who have previously failed an anti-TNF therapy. Initial 
results from the open label induction cohort (n=130 patients) showed that treatment with 
etrolizumab (105mg q4w) resulted in 50.8% of patients achieving a clinical response (≥3-point 
decrease and 30% reduction of MCS with a ≥1-point decrease in rectal bleeding score or rectal 
bleeding score ≤1) and 12.3% of patients achieving clinical remission (MCS ≤2, with individual 
subscores ≤1 and rectal bleeding score of 0) at week 14. Additionally, 43.9% of patients 
experienced a ≥1-point improvement from baseline endoscopic score, 52.3% were in rectal 
bleeding remission (rectal bleeding score of 0) and 35.4% were in stool frequency remission 
(stool frequency score ≤1 with ≥1-point reduction from baseline) at week 14; endoscopic 
improvement was associated with lower stool frequency scores and rectal bleeding 
remission. 
Emerging data, also presented in abstract form suggests that etrolizumab is effective in CD.163 
The ongoing, placebo-controlled Phase 3 study BERGAMOT is evaluating patients with 
moderate to severe CD who have been previously treated with immunosuppressants, 
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corticosteroids, and/or anti-TNFs. In the exploratory induction cohort, 300 patients were 
randomized 2:2:1 to receive subcutaneously etrolizumab 105mg every 4 weeks, etrolizumab 
210 mg on weeks 0, 2, 4, 8, and 12, or placebo during a 14-week period. Endpoints assessed 
included CDAI remission (CDAI <150), endoscopic improvement (≥50% reduction in Simple 
Endoscopic Score for Crohn’s Disease [SES-CD]) and symptomatic remission (abdominal pain 
<1 and loose/very soft stool frequency <3). CDAI remission was achieved at week 14 by 23.3% 
and 28.9% of patients receiving etrolizumab 105mg and 210mg, respectively, compared with 
16.9% of those receiving placebo. At week 14, treatment with both etrolizumab 105mg and 
210mg resulted in higher rates of endoscopic improvement compared with placebo (21.0% 
and 17.4% vs 3.4%, respectively). Symptomatic remission was achieved with both doses of 
etrolizumab as early as week 6 and observed consistently through week 14; 20.8% of 
etrolizumab 105mg and 24.8% of etrolizumab 210mg patients achieved symptomatic 
remission at week 14 compared with 11.9% of patients receiving placebo. 
Etrolizumab has been well tolerated in clinical studies reported to date, with no reported 
cases of PML, consistent with murine studies showing no role for β7 subunit containing 
integrin pairs in cell migration to the CNS.162,165 Adverse events, including infections, in the 
etrolizumab Phase 2 study in UC were similar between the etrolizumab and placebo arms.162 
Phase 3 trials in UC and CD are ongoing. 
Abrilumab (anti-α4β7 integrin) 
Abrilumab (AMG 181) is an IgG2 monoclonal antibody that, like vedolizumab, selectively binds 
the α4β7 integrin heterodimer.168 A first-in-human single ascending dose study confirmed 
AMG 181 to be safe and well tolerated with suitable pharmacokinetic and pharmacodynamic 
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profiles by subcutaneous injection.169 Phase 2 data in both moderate to severe CD and UC 
have recently been presented in abstract form.  
The Phase 2b CD trial included 249 adult patients who had failed corticosteroid, 
immunosuppressive or anti-TNF therapy.170 Participants had moderate to severe disease 
(CDAI 220-450) and evidence of active inflammation by endoscopy, or CRP or raised faecal 
calprotectin. Patients were randomised to placebo, a single subcutaneous 210mg dose of 
abrilumab, or repeated 21mg or 71mg doses of abrilumab by subcutaneous injection on day 
1 and at weeks 2 and 4, then every 4 weeks (Q4W) for up to 24 weeks. The primary endpoint 
was a CDAI remission score of <150 at week 8, and was not achieved in any treatment group. 
Secondary endpoints included remission at week 12 and a CDAI response at week 8 or 12 
(defined as a reduction of 100 points or more). CDAI response was observed in the 70mg Q4W 
group at week 8 and 12 (43.2% and 48.9% respectively) and the 210mg single dose group at 
week 12 (46.6%) with comparison to placebo response rates of 27% and 29.6% respectively 
at week 8 and 12. Higher remission was also observed in the 21mg Q4W group at week 12 
(41.7% compared to 17.6% in placebo). Stratifying according to prior anti-TNF use 
demonstrated greater efficacy in those who had failed anti-TNF therapy, where higher rates 
of remission were observed at week 12 in all treatment groups with remission also seen at 
week 8 in the 210mg single dose arm. Wide variation in placebo response rates were observed 
between anti-TNF-failure and anti-TNF-naïve patients which may have contributed to the lack 
of efficacy observed in this study.  
The Phase 2b UC study enrolled 354 patients with moderate to severe UC defined as a Mayo 
Score of 6-12 with an endoscopic score of ≥2.171 Subjects received placebo, a single 210mg 
subcutaneous dose of abrilumab, or repeated abrilumab dosing at 7mg, 21mg or 70mg on 
day 1, followed by week 2, week 4 and then every 4 weeks for 24 weeks. The primary endpoint 
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was remission at week 8 (defined as a total Mayo score of ≤2 with no individual subscore >1). 
Endoscopies were centrally read. Higher rates of remission were observed in the 70mg Q4W 
and 210mg single dose group compared to placebo (respectively, 13.5%, 13.4% and 4.4%). 
Response rates and mucosal healing rates were also higher in these treatment groups. 
In both the UC and CD studies no cases of PML were observed, adverse events were balanced 
between groups and no patients developed neutralising antibodies to the drug.170,171 Maximal 
receptor occupancy was observed in all treatment groups. Pharmacokinetic studies in the UC 
cohort indicated that maximal remission rates were observed in patients with drug serum 
trough-levels of >10µg/ml.171 
PF-00547659 (anti-MAdCAM-1) 
PF-00547659 is a subcutaneously delivered, fully humanized IgG2 anti-MAdCAM-1 
monoclonal antibody that blocks binding of α4β7 integrin to MAdCAM-1, thus is intended to 
reduce trafficking of α4β7+ leukocytes to the intestine.172 To demonstrate that this 
mechanism of action should not increase risk of PML, the TOSCA study enrolled 49 patients 
with moderate to severely active CD to undergo lumbar puncture and CSF analysis of 
lymphocyte populations.173 10 patients underwent two lumbar punctures 14 days apart to 
determine feasibility of identifying lymphocytes in CSF of patients with CD who had received 
prior immunosuppressants. Patients then received induction therapy with three doses of 
225mg PF-00547659 administered 4 weeks apart. The remaining 39 patients underwent CSF 
analysis before and after 12 weeks induction therapy. Consistent with blockade of 
α4β7:MAdCAM-1 interactions and thus impairment of lymphocyte trafficking to the gut, 
higher numbers of circulating β7+ memory T cells were observed in blood. In keeping with 
gut selectivity in mechanism of action, CSF analysis revealed no reduction in CSF T cell subsets 
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or CD4:CD8 ratio. Whilst 74% of patients at baseline had positive anti-JCV serology, no JCV 
virus DNA was detected in CSF from 19 patients tested following therapy. Open label analysis 
of efficacy using the HBI demonstrated clinical response (reduction in HBI of ≥3 points) in 80% 
and clinical remission (defined as an HBI of <5 points) in 79% of patients. The most common 
adverse events considered related to therapy included nasopharyngitis (16.3%), arthralgia 
(18.4%) and headache (12.2%). 
More recently double blind placebo controlled phase 2 trial data has been published from the 
TURANDOT study in UC,174 and the OPERA study in CD.175 In the TURANDOT trial, 357 patients 
with moderate to severely active UC (Mayo score ≥6 and endoscopic sub score ≥2) were 
randomised to placebo or 7.5mg, 22.5mg, 75mg or 225mg of PF-00547659 every 4 weeks. 
Remission rates at week 12 (defined as Mayo score ≤2with no subscore >1 and rectal bleeding 
subscore ≤1) were 2.7% in the placebo group. In the active treatment groups remission rates 
were 11.3% (7.5mg dose), 16.7% (22.5mg dose), 15.5% (75mg dose) and 5.7% (225mg). With 
comparison to placebo all doses except 225mg reached significance. In this induction study, 
adverse events were similar between placebo and PF-00547659 treated patients.  
In the OPERA trial, 265 patients with moderate to severe CD (defined as CDAI 220-450, CRP 
>3mg/L and ulcers on colonoscopy) who had failed treatment with anti-TNF therapy or 
immunosuppressants were randomised to placebo, 22.5mg, 75mg or 225mg of PF-00547659 
every 4 weeks.175 The primary end point of a decrease in CDAI of 70 points or more from 
baseline at week 8 or 12 was not reached, though outcomes may have been confounded by 
high CDAI placebo response rates. Pharmacological activity of the drug was evidenced by 
higher circulating β7+ memory T cells post therapy and a reduction in soluble MAdCAM-1. No 
adverse safety signal was identified across treatment groups or in comparison to placebo. 
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Oral integrin-targeted therapy in IBD  
The licensed and late-phase clinical trial anti-trafficking agents discussed so far are 
monoclonal antibodies that require intravenous or subcutaneous dosing. Successful 
development of oral therapeutics may potentially offer greater convenience to patients, and 
future development of small molecule therapies may allow targeting, not only of ligand 
binding, but alternate integrin-focused mechanisms of action such as conformational 
stabilisation.176 To date, two oral integrin-targeted compounds, AJM300 (carotegrast methyl) 
and PTG-100 have been studied for IBD. 
AJM300 is an oral small molecule antagonist of α4 integrin that targets both α4β7 and α4β1 
integrin. Experimental colitis induced by adoptive transfer of CD4+ T cells from IL-10-/- mice 
into SCID mice confirmed that oral treatment with AJM300 led to decrease of T lymphocytes 
within the LP, and reduced histopathological inflammatory score.177 A multiple-dose, 
randomised, double-blind clinical trial of 71 patients with active CD (defined as CDAI of 150 
or higher) has been presented in abstract form only.178 In this study AJM300 at doses of 40mg, 
120mg or 240mg three times daily for 8 weeks was compared to placebo. The primary end 
point was a decrease in CDAI from baseline to week 4 or later. Reductions in CDAI for those 
receiving AJM300 were not significantly different to placebo.  
More recently a double-blind, placebo controlled Phase 2a study of 102 patients with 
moderately active UC (Mayo Score of 6-10 with an endoscopic subscore of ≥2, and a rectal 
bleeding subscore of ≥1) has been reported.179 In this study patients were assigned to 960mg 
of AJM300 three times daily for 8 weeks or placebo. The primary end point was clinical 
response at week 8, defined as a decrease in Mayo Clinic Score of at least 3 points, with a 
decrease of at least 30% from baseline, and a decrease in the rectal bleeding subscore of 1 or 
more, or an absolute rectal bleeding subscore of 0 or 1. Clinical response at week 8 was 
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significantly greater in those receiving AJM300 at 62.7%, compared with 25.5% in the placebo 
group (p=0.0002). Higher rates of clinical remission and mucosal healing were also noted in 
those receiving AJM300. The proportion of patients previously treated with anti-TNF therapy 
and the relative outcome for this group were not reported. In common with other integrin-
targeted therapies an increase in peripheral circulating lymphocytes was observed. No 
serious adverse events, including no episodes of PML were reported. A Phase 3 programme 
studying AJM300 in UC is currently underway in Japan.180 
PTG-100 is an orally available α4β7 integrin-specific cysteine knot peptide under 
development by Protagonist Therapeutics. Animal studies presented in abstract form report 
a dose-dependent exposure of the peptide in GI tissue with a much lower exposure of the 
drug in blood.181 A Phase 2b multicenter, placebo controlled trial of this drug is currently 
recruiting, and will evaluate safety and efficacy of once daily doses of PTG-100 in moderate 
to severe UC.182  
Concluding remarks and positioning of anti-integrin therapy in IBD 
management 
Our understanding of integrin biology has led to the development of a new class of effective 
biological therapy in IBD. Vedolizumab is established in clinical practice, and several 
compounds that are in advanced clinical development may contribute additional effective 
treatment options for UC and CD. Integrin-targeted therapy can offer the potential of being 
gut-selective, which may be attractive in comparison to the systemic mechanism of action of 
anti-cytokine therapies including anti-TNF drugs and the recently licensed anti-p40 therapy 
ustekinumab. Anti-TNF therapy can induce rapid clinical response, such that this class of drug 
is now used in the setting of acute severe colitis.183 Ongoing head-to-head comparison trials 
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between anti-integrin therapies and anti-TNFs will help to better understand the relative 
efficacy and speed of impact of these classes of drugs.184-187 Once a patient achieves clinical 
remission, the durability of clinical remission is impressive with anti-trafficking 
agents.110,126,130,134,135 Long clinical experience with anti-TNFs have identified therapeutic drug 
levels as of importance for efficacy. At present the role of therapeutic drug monitoring for 
anti-integrin drugs is not firmly established, but with emerging evidence of serum trough 
level-efficacy relationships, particularly in UC, this is likely to be an important area of future 
study. 
Due to the excellent safety profile and good first-line efficacy of gut-selective anti-integrin 
therapy, in UC, European and Canadian guidance now recommends consideration of 
vedolizumab as a first-line biological therapy after incomplete response or failure to 5-
ASA.188,189 Given the known association of infections as an adverse effect in anti-TNF therapy, 
future algorithms may place vedolizumab as a first line therapy in higher risk, for example, 
older patients more at risk of respiratory disease. Further efficacy and safety data, including 
regarding treatment impact on extra-intestinal manifestations of IBD, and an improved 
understanding of discriminating mechanisms of action between anti-integrin therapies, as 
well as further exploration of therapeutic biomarkers for stratification or response to therapy 
may further alter treatment paradigms in the future.  
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Table 1: Integrin-targeted therapies for inflammatory bowel disease 
Agent Mechanism of 
action 
Class Indication Manufacturer Approval/Phase 
of clinical trial 
Natalizumab anti-α4 integrin subunit 
mAb 
(α4β7 & α4β1 activity) 
Humanised 
IgG4 mAb 
CD Biogen Licensed in USA 
Vedolizumab anti-α4β7 integrin dimer 
mAb 
Humanised 
IgG1 mAb 
CD/UC Takeda Licensed 
Etrolizumab anti-β7 integrin subunit 
mAb 
(αEβ7 & α4β7 activity) 
Humanised 
IgG1 mAb 
UC/CD Genentech/Roche Phase 3 
Abrilumab anti-α4β7 integrin dimer 
mAb 
Humanised 
IgG2 mAb 
CD/UC Amgen /Astra 
Zeneca/MedImmune 
Phase 2 complete 
AJM 300 
(carotegrast 
methyl) 
α4 integrin subunit 
antagonist 
Oral small 
molecule 
UC EA Pharma Phase 3 
PTG-100 α4β7 integrin-specific 
peptide 
Orally available 
peptide 
UC Protagonist 
Therapeutics 
Phase 2b 
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Figure legends 
 
 
Figure 1. Mammalian integrin αβ heterodimer pairing 
Twenty-four integrin heterodimer pairs have been identified in mammalian species and can 
be broadly grouped into functional categories, cellular expression or ligand specificity of 
receptors. The α4 and α9 subunits are restricted to chordates. Re-produced from Hynes99 
with permission from Elsevier. 
 
 50 
 
Figure 2: Chemo-attractant signaling triggers rapid integrin activation 
A. Integrin in resting bent “closed conformation”. B. Integrins are rapidly activated by 
intracellular signaling (“inside-out signaling”) cascades triggered by chemokine receptor 
stimulation. TCR stimulation can also activate integrins, but less rapidly. The signaling cascade 
depicted summarises chemokine mediated signaling during activation of αLβ2, as adapted 
from Toffali et al.4 Here chemokine interacting with its receptor leads to tyrosine kinase or G 
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protein activation of multiple rho small GTPases. In turn activation of Rho and Rap modules 
leads to regulation of the activity of several actin/integrin binding proteins. Chemokines 
trigger both conformational change and integrin motility and repositioning, both of which are 
important for cellular arrest during cell trafficking. In addition to chemokine mediated 
signaling, TCR activation of integrins regulates cell to cell interactions. Therefore, integrin 
targeted therapies may elicit a biological effect within lymphoid or target tissues, 
independent of their impact on cell trafficking. 
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Figure 3: Integrin involvement in T cell localisation to the gut lamina propria and epithelium 
T lymphocyte migration via HEVs in GALT and post-capillary venules in the lamina propria is 
controlled by initial microvillous presentation of receptors, initiating tethering and rolling 
along the endothelial surface. This process slows T lymphocytes sufficiently to allow the cells 
to sense chemokines presented by the endothelium. Chemokines trigger integrin activation 
(Figure 2), leading to strong integrin:CAM adhesion and cell arrest. Lymphocytes then 
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undergo diapedesis through the endothelial layer in response to motility signals from outside-
in integrin signaling and from chemoattractant gradients. In GALT, T cells use L-selectin for 
tethering and α4β7 for slow rolling on HEV. High levels of α4β7 on gut homing effector cells 
and blasts interacting with MAdCAM-1 can directly mediate rolling and arrest in the LP.15,19 
αLβ2:ICAM-1 interactions participate in terminal arrest on the endothelium, and may also 
promote cellular adhesion.19,52 High expression of α4β1 on effector T cells may allow α4β7-
independent interactions during inflammation in combination with L-selectin,12,57 especially 
in the inflamed ileum, a mechanism that may be important in CD.50 Lamina propria venules 
can also express P-selectin during inflammation to enhance tethering and rolling. Different 
lymphocyte populations can use distinct chemokine receptors for integrin activation and 
chemotaxis, conferring subset selectivity in recruitment (not shown). Once lymphocytes are 
within tissue, they may upregulate αEβ7 integrin and bind to epithelium through αEβ7:E-
cadherin interactions.  
